Ironwood Pharmaceuticals (IRWD) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

IRWD Ironwood Pharmaceuticals

Watchlist

8.025
-0.055-0.68%

Trading Apr 26 10:50 ET

1.28BMarket Cap-1244P/E (TTM)

Intraday

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Ironwood Pharmaceuticals to Host First Quarter 2024 Investor Update Call
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) today announced it will host its first quarter 2024 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, May 9, 2024. Individuals interested in
Businesswire16:01 ET
Investors in Ironwood Pharmaceuticals (NASDAQ:IRWD) From Five Years Ago Are Still Down 29%, Even After 8.6% Gain This Past Week
Ideally, your overall portfolio should beat the market average. But every investor is virtually certain to have both over-performing and under-performing stocks. So we wouldn't blame long term Ironw
Simply Wall StApr 24 07:18 ET
Ironwood Pharmaceuticals: A Strong Buy on Promising Gastrointestinal Treatment Prospects and Market Expansion Opportunities
TipRanksMar 28 14:37 ET
Express News | Ironwood Pharmaceuticals Announces Results From Phase 2 Exploratory STARGAZE Trial of Apraglutide For Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease
Moomoo 24/7Mar 28 07:33 ET
Ironwood Pharmaceuticals Announces Positive Results From Its Phase II Exploratory STARGAZE Trial of Apraglutide in Patients With Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease (SR GI AGVHD)
Results up to Day 91 show that apraglutide in SR GI aGVHD was well-tolerated with an acceptable safety profile, the study's primary objective.
Business WireMar 28 07:30 ET
Ironwood Pharmaceuticals (NASDAQ:IRWD): Analysts Stay Bullish Despite Recent Stock Plunge
TipRanksMar 16 12:36 ET

Comments

Luzi Ann Santos

Mar 1 00:54

ColumnsIronwood Pharma Shares Tank 40% as Drug Trial Misses Secondary Goal

$Ironwood Pharmaceuticals(IRWD.US)$ shares sank almost 40% after the drugmaker said its global phase III trial of Apraglutide, a treatment for short bowel syndrome, missed two of its four secondary goals.
That muddies the prospects for the company that's seeking to expand its product pipeline beyond Linzess.
Ironwood, which has been operating at a loss, sourced almost ll of its $117.6 million revenue in 2023 from its collaborati...

Meltyy

Feb 22 12:05

Biotech Stock Catalyst Watchlist

🎯 Ph 3 readouts in Q1 2024...
$Pfizer(PFE.US)$ Phase 3
$Palatin Technologies(PTN.US)$ Phase 3
$Annovis Bio(ANVS.US)$ Phase 3
$BioCardia(BCDA.US)$ Phase 3
$Atea Pharmaceuticals(AVIR.US)$ Phase 3
$Ironwood Pharmaceuticals(IRWD.US)$ Phase 3
$Alnylam Pharmaceuticals(ALNY.US)$ Phase 3
$Axsome Therapeutics(AXSM.US)$ Phase 3
$$Novocure(NVCR.US)$ Phase 3
$ROCHE HOLDING AG(RHHBY.US)$ Phase 3
$FibroGen(FGEN.US)$ Phase 3
$ACADIA Pharmaceuticals(ACAD.US)$ Phase 3
$Sellas Life Sciences(SLS.US)$...

Moomoo AI

Feb 18 22:16

Thomas McCourt's recent sale at the current share price of US$14.58 raises caution. More selling than buying by insiders over the past year and low insider ownership could concern potential investors.